Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action

被引：0
作者：
Bykova, Aleksandra [1 ,2 ]
Serova, Maria [1 ,3 ]
Chashkina, Maria [1 ]
Kosharnaya, Raisa [4 ]
Salpagarova, Zukhra [5 ]
Andreev, Denis [1 ]
Giverts, Ilya [6 ,7 ]
机构：
[1] Sechenov Univ, IM Sechenov First Moscow State Med Univ, NV Sklifosovsky Inst Clin Med, Dept Cardiol Funct & Ultrasound Diagnost, Bolshaya Pirogovskaya St 6-1, Moscow 119991, Russia
[2] Russian Acad Sci, Sci Res Inst Syst Anal, Dept Med Informat, Moscow, Russia
[3] City Clin Hosp 1, Moscow State Healthcare Inst, Dept Surg Treatment Complex Rhythm Disorders & Pac, Moscow, Russia
[4] Endocrinol Res Ctr, Dept Cardiol & Vasc Surg, Moscow, Russia
[5] Med Ctr ATLAS, Dept Cardiol, Moscow, Russia
[6] Maimonides Hosp, Dept Internal Med, New York, NY USA
[7] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA USA
来源：
CARDIAC FAILURE REVIEW | 2024年 / 10卷
关键词：
Glucagon-like peptide-1 receptor agonists; heart failure with preserved ejection fraction; diabetes; obesity; atrial fibrillation; coronary artery; disease; arterial hypertension; TYPE-2; DIABETES-MELLITUS; MAJOR CARDIOVASCULAR EVENTS; GLUCOSE-LOWERING AGENTS; GLP-1; RECEPTOR; ATRIAL-FIBRILLATION; DOUBLE-BLIND; CONTROLLED-TRIAL; ADIPOSE-TISSUE; LIRAGLUTIDE; EXENATIDE;
D O I：
10.15420/cfr.2024.06
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction (HFpEF). Traditional heart failure treatment modalities have shown limited success in improving outcomes for patients with HFpEF, but new evidence suggests that GLP-1RAs could be beneficial. The positive effects of GLP-1RAs are likely due to their ability to reduce systemic inflammation, enhance metabolism and directly affect the cardiovascular system, addressing critical aspects of HFpEF pathology. However, the exact impact of GLP-1RAs on clinical outcomes for different HFpEF phenotypes is still unclear. This review highlights both the potential benefits and the current limitations of GLP-1RA therapy, suggesting a careful approach for their application in clinical practice.
引用
收藏
页数：8
相关论文
共 82 条
  • [1] Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
    Al-Sadawi, Mohammed A.
    Aslam, Faisal M.
    Tao, Michael
    Alsaiqali, Mahmoud
    Almasry, Ibrahim O.
    Fan, Roger
    Rashba, Eric J.
    Singh, Abhijeet
    [J]. IJC HEART & VASCULATURE, 2023, 47
  • [2] Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association and the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
    Anker, Stefan D.
    Usman, Muhammad Shariq
    Anker, Markus S.
    Butler, Javed
    Boehm, Michael
    Abraham, William T.
    Adamo, Marianna
    Chopra, Vijay K.
    Cicoira, Mariantonietta
    Cosentino, Francesco
    Filippatos, Gerasimos
    Jankowska, Ewa A.
    Lund, Lars H.
    Moura, Brenda
    Mullens, Wilfried
    Pieske, Burkert
    Ponikowski, Piotr
    Gonzalez-Juanatey, Jose R.
    Rakisheva, Amina
    Savarese, Gianluigi
    Seferovic, Petar
    Teerlink, John R.
    Tschoepe, Carsten
    Volterrani, Maurizio
    von Haehling, Stephan
    Zhang, Jian
    Zhang, Yuhui
    Bauersachs, Johann
    Landmesser, Ulf
    Zieroth, Shelley
    Tsioufis, Konstantinos
    Bayes-Genis, Antoni
    Chioncel, Ovidiu
    Andreotti, Felicita
    Agabiti-Rosei, Enrico
    Merino, Jose L.
    Metra, Marco
    Coats, Andrew J. S.
    Rosano, Giuseppe M. C.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (07) : 936 - 955
  • [3] Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis
    Ansari, Huzaifa Ul Haq
    Qazi, Shurjeel Uddin
    Sajid, Faiza
    Altaf, Zahabia
    Ghazanfar, Shamas
    Naveed, Naveen
    Ashfaq, Amna Shakil
    Siddiqui, Abdul Hannan
    Iqbal, Hamza
    Qazi, Sana
    [J]. ENDOCRINE PRACTICE, 2024, 30 (02) : 160 - 171
  • [4] PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
    Aroda, Vanita R.
    Rosenstock, Julio
    Terauchi, Yasuo
    Altuntas, Yuksel
    Lalic, Nebojsa M.
    Morales Villegas, Enrique C.
    Jeppesen, Ole K.
    Christiansen, Erik
    Hertz, Christin L.
    Haluzik, Martin
    [J]. DIABETES CARE, 2019, 42 (09) : 1724 - 1732
  • [5] Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans
    Bharucha, Adil E.
    Charkoudian, Nisha
    Andrews, Christopher N.
    Camilleri, Michael
    Sletten, David
    Zinsmeister, Alan R.
    Low, Phillip A.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2008, 295 (03) : R874 - R880
  • [6] Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
    Bohne, Loryn J.
    Jansen, Hailey J.
    Dorey, Tristan W.
    Daniel, Irene M.
    Jamieson, K. Lockhart
    Belke, Darrell D.
    Mcrae, Megan D.
    Rose, Robert A.
    [J]. JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (08): : 922 - 936
  • [7] Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
    Borlaug, Barry A.
    Paulus, Walter J.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 (06) : 670 - +
  • [8] DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
    Buse, John B.
    Drucker, Daniel J.
    Taylor, Kristin L.
    Kim, Terri
    Walsh, Brandon
    Hu, Hao
    Wilhelm, Ken
    Trautmann, Michael
    Shen, Larry Z.
    Porter, Lisa E.
    [J]. DIABETES CARE, 2010, 33 (06) : 1255 - 1261
  • [9] Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease
    Chien, Chiang-Ting
    Fan, Shih-Chen
    Lin, Shao-Chieh
    Kuo, Chang-Chih
    Yang, Chih-Hui
    Yu, Tzu-Ying
    Lee, Shih-Pin
    Cheng, Dai-Yu
    Li, Ping-Chia
    [J]. THROMBOSIS AND HAEMOSTASIS, 2014, 112 (05) : 1051 - 1064
  • [10] Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction A Randomized Controlled Trial
    Chieng, David
    Sugumar, Hariharan
    Segan, Louise
    Tan, Caleb
    Vizi, Donna
    Nanayakkara, Shane
    Al-Kaisey, Ahmed
    Hawson, Joshua
    Prabhu, Sandeep
    Voskoboinik, Aleksandr
    Finch, Sue
    Morton, Joseph B.
    Lee, Geoffrey
    Mariani, Justin
    La Gerche, Andre
    Taylor, Andrew J.
    Howden, Erin
    Kistler, Peter M.
    Kalman, Jonathan M.
    Kaye, David M.
    Ling, Liang-Han
    [J]. JACC-HEART FAILURE, 2023, 11 (06) : 646 - 658
123456789